Ref: STEX/OUTCOME/2026-27 **Date: 14.08.2026**

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai- 400051

Scrip Code- 539148

Symbol- SHIVALIK

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on June 30, 2026.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

a) Statement showing the Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026 as **Annexure-A** and

b) Unaudited Segment-wise Revenue, Results, Assets and Liabilities of the Company, both Standalone and Consolidated, for the Quarter ended June 30, 2026; as **Annexure-B** and

c) Limited Review Report from M/s Rahul Chaudhary & Associates, Chartered Accountants on the Un-Audited Financial Results (Standalone & Consolidated) as **Annexure-C**

Further Board of Directors at their meeting approved the following resolutions:

a) Approved draft Annual Report for the financial year 2025-26.

b) The 48th AGM of the Company will be held on Monday the September 28, 2026 at 1:00 pm at Hotel Saffron Leaf, GMS Road Dehradun, Uttarakhand-248146.

Pursuant to rule 20(4)(vii) of the Companies (Management and Administration) Rules, 2014, the Company has fixed Monday, September 21, 2026 as the cut-off date for the purpose of determining the eligible shareholders (holding shares either in physical or dematerialised form) to cast their vote electronically from Friday, September 25, 2026 to Sunday, September 27, 2026.

In compliance of SEBI (LODR), Regulations, 2015 the Board of Directors of the Company have decided to close the Register of Members and other Transfer books of the Company with a view to enable the Company to make payment of Final Dividend @10% or Rs. 0.50 per Equity Share (if decided by the members in their forthcoming AGM) for the Financial year 2025-26. The aforesaid register will remain close from Tuesday, September 22, 2026 to Monday, September 28, 2026 (both days inclusive)

The meeting of the Board of Directors commenced 03:45 p.m. and concluded at 5:00 p.m.

The Un-Audited Financial Results (Standalone & Consolidated) of the Company for the quarter ended on June 30, 2026, as approved by the Board, will also be available on the Company's website at www.shivalikrasayan.com.

This is for your information and records.

Thanking You.

Yours faithfully,

For Shivalik Rasayan Limited

Parul Arora
Digitally signed by Parul Arora
Date: 2026.08.14 16:42:46 +05'30'

Parul Choudhary
Company Secretary & Compliance Officer
ACS: 34854

Annexure-A

Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007

CIN : L24237UR1979PLC005041

E-mail : cs@shivalikrasayan.com, www.shivalikrasayan.com

Un-audited Standalone and Consolidated Financial Results for the Quarter ended on 30th June 2026

PART I — All Figures in Rs. Lakhs Excepts Earning Per Shares

	Particulars	Standalone				Consolidated			
		Three month period ended			Year Ended	Three month period ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026	30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Un-audited	Un-audited	Un-audited	Audited	Audited	Un-audited	Un-audited	Audited
1	**Income from operations**								
	(a) Net Sales/Income from operations	4,844.16	4,216.91	4,626.45	17,023.35	9,633.85	10,281.57	8,930.93	36,800.32
	(b) Other Income	10.36	18.12	12.68	96.45	96.52	191.64	59.71	407.76
	Total Revenue	**4,854.52**	**4,235.03**	**4,639.13**	**17,119.80**	**9,730.37**	**10,473.21**	**8,990.64**	**37,208.09**
2	**Expenses**								
	a) Cost of Material Consumed	3,015.99	2,308.10	2,075.91	10,264.52	5,277.06	4,917.33	4,535.68	19,699.33
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	-220.74	23.25	435.88	(1,604.28)	(369.79)	633.66	247.39	(861.89)
	d) Employees Benefits Expenses	588.14	624.41	591.54	2,586.16	1,519.52	1,564.32	1,400.57	6,055.47
	e) Finance Cost	125.09	207.40	146.43	610.26	207.97	245.70	261.77	960.00
	f) Depreciation and Amortisation Expenses	262.50	242.55	301.41	1,154.81	441.19	415.87	481.54	1,876.67
	g) Other expenses	774.86	562.66	886.42	3,159.20	2,088.56	1,923.69	1,649.05	7,330.95
	Total Expenses	**4,545.84**	**3,968.37**	**4,437.59**	**16,170.67**	**9,164.52**	**9,700.58**	**8,576.00**	**35,060.52**
3	**Profit/(Loss) before Exceptional Items & Tax (1-2)**	**308.68**	**266.66**	**201.54**	**949.13**	**565.85**	**772.63**	**414.64**	**2,147.57**
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Year)	-	-	-	-	-	-		-
5	**Profit/(Loss) before Extra Ordinary Items & Tax (3-4)**	**308.68**	**266.66**	**201.54**	**949.13**	**565.85**	**772.63**	**414.64**	**2,147.57**
6	**Tax Expenses**								
	Current Year	100.10	(61.76)	52.92	202.27	183.10	3.52	109.88	457.10
	MAT Credit Entitlement	-46.16	108.35	(17.71)	(36.44)	(46.16)	108.35	(17.71)	(36.43)
	Deferred Tax Liability	-10.78	(52.55)	44.25	(33.95)	(21.22)	(56.56)	40.34	(69.98)
	Total Tax Expenses	**43.16**	**(5.96)**	**79.46**	**131.88**	**115.72**	**55.31**	**132.50**	**350.69**
7	**Net Profit/Loss for the period (5-6)**	**265.52**	**272.62**	**122.08**	**817.25**	**450.13**	**717.32**	**282.13**	**1,796.88**
8	**Other Comprehensive Income**								
	Item that will not be reclassified to Profit & Loss	-	-	-	-	-	-	-	-
	Total Comprehensive income Net of Tax	**265.52**	**272.62**	**122.08**	**817.25**	**450.13**	**717.32**	**282.13**	**1,796.88**
9	**Total Comprehensive income for the Period (7+8)**	**265.52**	**272.62**	**122.08**	**817.25**	**450.13**	**717.32**	**282.13**	**1,796.88**
10	**Net Profit/ (loss) attribuitable to**								
	a) Controlling Interest	**265.52**	**272.62**	**122.08**	**817.25**	**340.23**	**452.54**	**160.05**	**1,213.60**
	b) Non Controlling Interest	-	-	-	-	**109.89**	**264.77**	**122.08**	**583.27**
11	Paid-up equity share capital (Rs.5/- per share)	787.52	787.52	787.52	787.52	787.52	787.52	787.52	787.52
12	**Earning Per Share (Rs.)**								
	(a) Basic	1.69	1.73	0.78	5.19	2.16	2.87	1.02	7.71
	(b) Diluted	1.69	1.73	0.78	5.19	2.16	2.87	1.02	7.71

NOTES :

1. The Un-audited financial results for the quarter ended on 30.06.2026 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.08.2026.
2. The figures are regrouped in previous year also, wherever considered necessary.
3. The company operates in business segment viz Agro Chemical, Pharma API & Pharma Formulations.
4. The Earning Per Share has been calculated as per Ind AS-33.
5. Consolidated results of the company includes the results of its Associate i.e., Medicamen Biotech Limited.
6. The figures of the quarter ended on 31.03.2026 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the financial year ended on 31.03.2026

For & on behalf of Board of Directors
Shivalik Rasayan Limited

SHIVALIK RASAYAN LIMITED New Delhi

R. Bishnoi

(Rahul Bishnoi)
Chairman

Place : New Delhi
Dated : 14.08.2026

Shivalik Rasayan Ltd.

Regd. Office: Village Kolhupani, P.O. Chandanwari, Dehradun- 248007
CIN : L24237UR1979PLC005041
E-mail : cs@shivalikrasayan.com, www.shivalikrasayan.com

Un-audited Standalone & Consolidated segment wise revenue, results, assets and liabilities for the Quarter Ended 30th June 2026

Sl. No.	Particulars	Standalone				Consolidated			
		Three months period ended			Year Ended	Three month period ended			Year Ended
		30-06-2026	31-03-2026	30-06-2025	31-03-2026	30-06-2026	31-03-2026	30-06-2025	31-03-2026
		Un-audited	Audited	Un-audited	Audited	Un-audited	Audited	Un-audited	Audited
1	**Segment revenue**								
	A. Agrochemicals	4,382.58	3,443.76	4,433.88	15,125.67	4,382.58	3,443.76	4,433.88	15,125.67
	B. Active Pharma Ingredient (API)	217.91	474.42	192.52	904.79	217.91	474.42	192.52	904.79
	C. Pharma Formulation	-	-	-	-	4,789.69	6,064.66	4,304.48	19,776.97
	D. Unallocated other operating revenue	243.67	298.73	0.06	992.89	243.67	298.73	0.06	992.89
	Total Revenue	**4,844.16**	**4,216.91**	**4,626.45**	**17,023.35**	**9,633.86**	**10.281.57**	**8,930.93**	**36,800.32**
2	**Segment results**								
	A. Agrochemicals	631.34	268.22	643.92	2,202.11	631.34	268.22	643.92	2,202.11
	B. Active Pharma Ingredient (API)	(197.56)	205.85	(295.95)	(642.72)	(197.56)	205.85	(295.95)	(642.72)
	C. Pharma Formulation	-	-	-	-	340.05	544.27	328.44	1,548.18
	Sub Total	**433.78**	**474.06**	**347.98**	**1,559.38**	**773.84**	**1,018.33**	**676.41**	**3,107.57**
	Less:Finance costs	125.09	207.40	146.43	610.26	207.97	245.71	146.43	960.00
	Less: Unallocable expenditure net of unallocable income	-	-	-	-	-	-	-	-
	Profit before exceptional items and tax	**308.70**	**266.66**	**201.54**	**949.13**	**565.87**	**772.64**	**529.98**	**2,147.56**
	Exceptional Items	-	-	-	-	-	-	-	-
	Profit/(Loss) before tax	**308.70**	**266.66**	**201.54**	**949.13**	**565.87**	**772.64**	**529.98**	**2,147.56**
	Less: Tax Expenses	43.16	(5.96)	79.46	131.88	115.72	55.31	132.50	350.69
	Net Profit/(Loss) for the period/year	**265.54**	**272.62**	**122.08**	**817.26**	**450.15**	**717.33**	**397.48**	**1,796.88**
3	**Segment assets**								
	A. Agrochemicals	31,272.89	31,712.12	32,683.30	31,712.12	31,272.89	31,712.12	32,683.30	31,712.12
	B. Active Pharma Ingredient (API)	12,556.54	12,569.22	11,178.82	12,569.22	12,556.54	12,569.22	11,178.82	12,569.22
	C. Pharma Formulation	-	-	-		36,053.14	35,608.64	33,097.08	35.608.64
	D. Unallocated	-	-	-		-	-	-	-
4	**Total**	**43,829.43**	**44,281.34**	**43,862.11**	**44,281.34**	**79,882.58**	**79,889.98**	**76,959.20**	**79,889.98**
	Segment liabilities								
	A. Agrochemicals	5,841.20	5,978.09	16,089.49	5,978.09	5,841.20	5,978.09	16,089.49	5,978.09
	B. Active Pharma Ingredient (API)	1,447.51	1,209.77	611.96	1,209.77	1,447.51	1,209.77	611.96	1,209.77
	C. Pharma Formulation	-	-	-		4,396.36	4,846.77	3,650.74	4,846.77
	D. Unallocated	-	-	-		-	-	-	-
	Total	**7,288.71**	**7.187.86**	**16,701.45**	**7,187.86**	**11,685.07**	**12,034.63**	**20,352.18**	**12,034.63**

For & on behalf of Board of Directors
Shivalik Rasayan Limited

SHIVALIK RASAYAN LIMITED New Delhi

Place : New Delhi
Dated : 14.08.2026

(Rahul Bishnoi)
Chairman

RAHUL CHAUDHARY & ASSOCIATES
Chartered Accountants

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF SHIVALIK RASAYAN LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To
The Board of Directors,
Shivalik Rasayan Ltd.
Village Kolhupani, P.O.
Chandanwari, Dehradun-248007

We have reviewed the accompanying statement of unaudited financial results of M/s Shivalik Rasayan Limited having its Corporate Office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter ended on June 30, 2026 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors at their respective meeting held on August 14, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rahul Chaudhary & Associates
Chartered Accountants
Firm Reg. No. 033971N

Chaudhary

Rahul Chaudhary & Associates * Faridabad * Chartered Accountants

CA Rahul Chaudhary
Proprietor
M. No. 542837
UDIN: 26542837LMRAPV6677

Place: Faridabad
Date: 14.08.2026

Reg. Office: - T4-204, Zion Lake View Apartment, Sector-48, NIT, Faridabad-121001
Email ID: - ca.chaudhary19@gmail.com, Contact No: - 9811372158

LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL RESULTS OF SHIVALIK RASAYAN LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To
The Board of Directors,
Shivalik Rasayan Ltd.
Village Kolhupani, P.O.
Chandanwari, Dehradun-248007

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of SHIVALIK RASAYAN LIMITED ("the Parent") and its associate (the Parent and its associate together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter ended on June 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and reviewed by the parent's Audit Committee and approved by the Parent's Board of Directors at their respective meetings held on August 14, 2026, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules made there under and other accounting principles generally accepted in India and Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the Medicamen Biotech Limited (the "Associate" Company)

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid id Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

Rahul Chaudhary & Associates
Chartered Accountants
Faridabad

7. We did not review the interim financial information of Associate included in the consolidated unaudited financial result, the Group's share of net profit after tax of Rs. 74.68 Lakhs for the quarter ended on June 30, 2026, as considered in the consolidated unaudited financial results, in respect of an associate, based on their interim financial information which has been reviewed by other auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.

For Rahul Chaudhary & Associates
Chartered Accountants
Firm Reg. No. 033971N

Rahul Chaudhary & Associates
Chartered Accountants
Faridabad

CA Rahul Chaudhary
Proprietor
M. No. 542837
UDIN: 26542837TAJSIV8449

Place: Faridabad
Date: 14.08.2026